Researcher seeks safer, more effective leukemia treatment

Date:
August 4, 2020
Source:
University of Arizona Health Sciences
Summary:
A potentially safer, more effective chemotherapy treatment for
patients with blood-related cancers, such as leukemia, who need
a particular bone marrow transplant procedure is under study. The
procedure is known as a haploidentical (half-matched) bone marrow
transplantation, or ''haplo- BMT,'' providng an alternate source
of stem cells for patients needing a bone marrow transplant but
unable to find a perfect or near-perfect donor match for human
leukocyte antigens.



FULL STORY ==========================================================================
A potentially safer, more effective chemotherapy treatment for patients
with blood-related cancers, such as leukemia, who need a particular bone
marrow transplant procedure is under study at the University of Arizona
Health Sciences.


==========================================================================
The procedure is known as a haploidentical (half-matched) bone marrow transplantation, or "haplo-BMT," providng an alternative source of stem
cells for patients who need a bone marrow transplant but are unable to
find a perfect or near-perfect donor match for human leukocyte antigens
(HLA). These HLA are proteins the immune system uses to identify cells
that belong in the body and those that do not. Haplo-BMT allows for a
donor to have only half the matching proteins -- which can be lifesaving
for the many patients who need a bone marrow transplant.

Haplo-BMT has been critically important in improving survivability
for patients who lack a perfect match, a problem more prevalent among
minority populations.

Less than 40% of Hispanic and less than 20% of African American patients
will successfully have a match in the national or international
registries, compared to nearly 80% of white patients, said Emmanuel
Katsanis, MD, professor in the Departments of Pediatrics, Medicine,
Pathology and Immunobiology at the UArizona College of Medicine --
Tucson, director of the adult and pediatric hematopoietic cellular
therapy and transplant program at Banner -- University Medicine and
the UArizona Cancer Center, and a researcher at the UArizona Steele
Children's Research Center.

For several years, Dr. Katsanis has introduced to patients the relatively
new and life-saving haplo-BMT treatments. The most commonly used protocols begin with chemotherapy, followed by the transplant from the half-matched donor.

After the transplant, a patient is given more chemotherapy with the drug cyclophosphamide to leave the patient stem cells and non-reactive T-cells
to fight certain infections. Nevertheless, Dr. Katsanis is hopeful to
uncover an even more effective chemotherapy drug.

"The current standard treatment with cyclophosphamide is effective," Dr.

Katsanis said. "However, it can also suppress the donor T-cells
from attacking the leukemia. Therefore, we hypothesized other drugs
may work similarly and, hopefully, better than cyclophosphamide. We
found in previous research in our laboratory, which was published
in the British Journal of Haematology, a journal of the British
Haematology Society, that one of those drugs was bendamustine."
Based on those findings, Dr. Katsanis wrote a Phase I clinical trial
titled, "Haploidentical BMT with Post-Transplant Cyclophosphamide and Bendamustine" (ClinicalTrials.gov identifier: NCT02996773). This trial
was established to test bendamustine in humans, and Dr. Katsanis recently reported preliminary results in an interim analysis published in eJHaem, another British Haematology Society journal.

"The early results from this first half of the Phase 1 trial have
shown bendamustine is well-tolerated," Dr. Katsanis said. "It may have advantages to recovering white blood cell counts and platelets earlier,
and less susceptibility to regenerating viral infections, such as cytomegalovirus (CMV) infection. We saw a statistically significant
reduction in CMV," a noteworthy posttransplant complication.

Dr. Katsanis' expertise in haplo-BMT also has produced promising findings
for pediatric and young adult patients. He and a team of researchers
recently published in Frontiers in Pediatrics the largest pediatric study
of its kind to date in North America. The study demonstrated that of 21 pediatric and young adult patients who received haplo-BMT for hematlogic malignancies (cancers that affect the blood, bone marrow and lymph nodes)
at Banner Children's at Diamond Children's Medical Center, 84% were alive
with a median follow-up of more than two years." That survival rate is
a significant result, providing hope for patients and their families.

"Haplo-BMT is expanding throughout the world," Dr. Katsanis said. "This treatment is easier, faster and less expensive to find a donor. Now,
we are trying to make it even safer and more effective for patients."

========================================================================== Story Source: Materials provided by
University_of_Arizona_Health_Sciences. Note: Content may be edited for
style and length.


========================================================================== Journal Reference:
1. Emmanuel Katsanis, Lauren N. Sapp, Susie Cienfuegos Reid, Naresh
Reddivalla, Baldassarre Stea. T-Cell Replete Myeloablative
Haploidentical Bone Marrow Transplantation Is an Effective
Option for Pediatric and Young Adult Patients With High-Risk
Hematologic Malignancies. Frontiers in Pediatrics, 2020; 8 DOI:
10.3389/fped.2020.00282 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2020/08/200804093309.htm

--- up 2 weeks, 6 days, 1 hour, 55 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1337:3/111)